

1 **Full title: EBV deletions as biomarkers of response to treatment of Chronic Active Epstein**

2 **Barr Virus**

3 Authors: Venturini Cristina¹, Houldcroft Charlotte J², Lazareva Arina³, Wegner Fanny¹,
4 Morfopoulou Sofia¹, Amrolia Persis J.³, Golwala Zainab⁴, Rao Anupama⁴, Marks
5 Stephen D.^{5,6}, Simmonds Jacob⁴, Yoshikawa Tetsushi⁷, Farrell Paul J.⁸, Cohen Jeffrey I.⁹,
6 Worth Austen J¹⁰, Breuer Judith^{1,4}

7 Affiliations:

8 ¹ Institute of Child Health, University College London, London, UK

9 ² Department of Medicine, University of Cambridge, Cambridge, UK

10 ³ Bone Marrow Transplantation Department, Great Ormond Street Hospital for Children NHS
11 Foundation Trust, London, UK

12 ⁴ Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK

13 ⁵ Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS
14 Foundation Trust, London, UK

15 ⁶ University College London Great Ormond Street Institute of Child Health, NIHR Great Ormond
16 Street Hospital Biomedical Research Centre, London, UK

17 ⁷ Department of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan.

18 ⁸ Section of Virology, Department of Infectious Disease, Imperial College Faculty of Medicine,
19 London, UK

20 ⁹ Laboratory of Infectious Disease, National Institute of Allergy and Infectious Diseases,
21 Bethesda, Maryland, USA

22 ¹⁰ Department of Immunology, Great Ormond Street Hospital for Children NHS Foundation
23 Trust, London, UK

24

25 Corresponding author: Judith Breuer, Division of Institute Child Health, University College London,
26 30 Guilford St, Holborn, London WC1N 1EH. Contact email: j.breuer@ucl.ac.uk

27

28 Key points:

- 29 • Unique EBV deletions are found in European CAEBV patients.
- 30 • Loss of deletions occurs following effective treatment and may prove useful in the
- 31 management of disease.

32

33 Abstract:

34 Chronic active Epstein Barr Virus (CAEBV) is a rare and severe condition occurring in previously
35 healthy individuals associated with persistent EBV viraemia, fever, lymphadenopathy and
36 hepatosplenomegaly.

37 Specific deletions in the EBV genome have been found in CAEBV and certain lymphomas. However, it
38 is unclear how stable these deletions are, whether they are present in different sites and how they
39 evolve in response to treatment. We sequenced fifteen longitudinal blood samples from three
40 CAEBV patients, comparing the results with 13 saliva samples from CAEBV patients and sequences
41 from benign (both primary infection and reactivation) and malignant EBV-related conditions. We
42 observed large EBV deletions in blood, some of which are predicted to disrupt viral replication, but
43 not saliva from patients with CAEBV. Deletions were stable over time but were lost following
44 successful peripheral blood stem cell transplants (PBSCT) or in one case, treatment with rituximab.
45 Our results are consistent with the likelihood that certain deletions occurring in virus from patients
46 with CAEBV are associated with the evolution and persistence of haematological clones. We propose
47 that the loss of EBV deletions following successful treatment should be investigated as a potential
48 biomarker to aid management of CAEBV.

49

50

51

52 Introduction

53 Epstein-Barr virus (EBV) infects >95% of the population worldwide ¹. A small number of patients
54 develop life-threatening persistence of high level/sustained EBV replication following an infectious
55 mononucleosis syndrome, often associated with splenomegaly and hepatitis ². Chronic active EBV
56 (CAEBV) (see “clinical definitions in Supplementary) is characterised by infiltration of tissues by EBV
57 positive T, NK or less frequently B cells and can progress into lymphoproliferative disease. Clonal
58 expansion of EBV-infected T or NK cells is well described ^{3,4}.

59

60 To date, CAEBV has been mostly described in Asian or South/Central American patients ⁵. Frequent
61 deletions in the EBV genome have been found in samples from Japanese CAEBV patients (35%) and
62 other EBV-driven neoplasms ⁶⁻⁸. However, it is unclear if these deletions are specific for Asian EBV
63 strains, whether they are present in viral genomes in different sites and how they evolve overtime.

64

65 We sequenced EBV from serial blood samples obtained from three UK patients with CAEBV. The
66 results were compared with sequences from saliva of CAEBV patients and blood and tissue from
67 other benign and malignant EBV-related conditions.

68

69 Methods

70 Study design

71 Fourteen blood samples from three CAEBV patients from Great Ormond Street Hospital (GOSH)
72 were sequenced (Table 1 and Supplementary). All three received Rituximab, following which
73 patient 2 became asymptomatic. Patients 1 and 3 received peripheral blood stem cell transplants
74 (PBSCTs) due to relapse of EBV driven HLH. The data were compared with 67 EBV sequences from
75 asymptomatic and other CAEBV patients, infectious mononucleosis (IM), post transfusion
76 lymphoproliferative disease (PTLD), post solid organ transplant viraemia and lymphomas from
77 different body-compartments (Table S1).

78 **Statistical and sequence analysis**

79 Samples were sequenced and analysed using a standard pipeline (Supplementary).

80 Diversity calculations and haplotype reconstruction have been described elsewhere^{9,10}. All other

81 statistical analyses were done with in-house R scripts¹¹.

82

83 **Results and discussion**

84 **EBV genomes in blood and saliva from CAEBV patients**

85 EBV blood genomes from CAEBV patients clustered with European/US sequences; longitudinal

86 samples, including those after PBSCT, clustered by patient (Supplementary figure 2). Within-host

87 CAEBV nucleotide diversity (π) was low and comparable to that of EBV from other blood samples

88 (Table S1 and Supplementary figure 4-5). In contrast CAEBV salivary samples showed significantly

89 higher EBV diversity compared to blood and tumour samples ($p < 0.001$), indicating the presence of

90 multiple strains (Supplementary figure 6-8). Single nucleotide variants (SNVs) and small (<2kbp)

91 deletions were present in all samples, largely located in latent genes as well as BPLF1 and BLLF1

92 [gp350] (Supplementary figures 9-17). Our results showed that EBV shed in saliva has the hallmarks

93 of lytic replication and frequent mixed infections in line with previous studies^{12,13}.

94 **Larger Deletions**

95 We identified low frequency larger (>2kb) EBV deletion in patient 1, as well as PTLD (2/4) and HL

96 (2/7) tumour-tissue at position 120470-158062 (figure 1). This includes the BART miRNA clusters, as

97 well as several lytic genes, including scaffold proteins (i.e. BdRF1, BVRF2), glycoproteins (i.e. BILF2,

98 BXLF2), a tegument protein (BVRF1), and regulators of late gene transcription (BcRF1, BVLF1).

99 Interestingly, patient 1 also had a nonsense mutation in BXLF2. A second larger deletion at positions

100 12118-15159, which is part of the major EBV repeat (IR1) was present in blood from CAEBV patients

101 (4/4) and one patient with PID.

102 **EBV variation overtime in CAEBV patients**

103 Analysis of variation overtime revealed that the blood from two CAEBV patients (1 and 3) with EBV
104 present predominantly in T cells, showed higher EBV genomic heterogeneity with increasing number
105 of low frequency (<50%) variants and deletions than patients with IM (Figure 1D, Supplementary
106 figures 19-20). In contrast, patient 2, whose EBV was only found in B cells, had fewer SNVs and
107 deletions with a picture similar to that seen in the blood from patients with PTLD with evidence of
108 clonality. In patient 2, larger deletions were stable overtime but were lost after rituximab (Figure
109 1D). In CAEBV patient 1, larger deletions persisted despite rituximab. Associated clinical
110 deterioration necessitated PBSCT (Table 1), following which both SNVs and deletions were absent
111 from virus reactivating asymptotically. CAEBV patient 3, who also failed to respond to rituximab,
112 lost most deletions, including the 12118-15159 IR1 deletion following PBSCT.

113 Discussion

114 EBV deletions were previously described only in CAEBV and malignancies patients of Asian origins ⁶⁻
115 ⁸, however we show that these deletions occur independently of geographic origin. Data from
116 mouse models suggest that loss of the BART miRNAs and late lytic genes within 120470-158062
117 deletion may drive a more lytic phenotype and faster cell growth, this predisposing to tumour
118 formation ^{8,14,15}. Although, the mechanism is not entirely clear, Murata and colleagues argue that the
119 abortive EBV replication resulting from the absence of these regions prevents normal cell death
120 associated with lytic replication ^{8,16}.

121 The 12118-15159 deletion overlaps with the IR1 which includes BWRF1 and Wp promoters. There is
122 no direct evidence yet that BWRF1 is biologically significant, however it is known that some
123 components are essential for the transformation of cells by EBV ¹⁷. Our deletion is similar to one
124 identified in strain L591, a Hodgkin's lymphoma cell line (breakpoint 125bp upstream of hairpin) ^{17,18}.
125 Persistence in longitudinally sampled blood of larger deletions has been associated with clonal
126 expansion of the cells in which they are found ⁶. Importantly we show that clinical response to
127 therapy is associated with loss of deletions in virus recovered after treatment. Our findings of low-

128 level potentially premalignant clones together with evidence of replicating virus in blood from
129 patients with CAEBV fits with the hypothesis that deletions occur only when a particular subset of
130 the patient's blood cells are infected with EBV. Progenitor lymphoid cells have been suggested to be
131 the target cell type¹⁶.

132

133 In conclusion, we confirm that clones containing EBV genomes with specific large deletions are
134 found in blood but not saliva from CAEBV patients. While rituximab reduced the burden of EBV
135 deletions in the blood of B cell-associated CAEBV, it had no impact on the prevalence of EBV
136 deletions in T/NK-associated CAEBV. The absence of these EBV-deletions from virus reactivating
137 following PBSCT suggests the loss of the pre-malignant clone and raises the possibility that these
138 large deletions could be useful biomarkers for monitoring the success of treatments for CAEBV.

139

140 **Data availability:**

141 Sequence reads for CAEBV and PID patients have been deposited in the European Nucleotide
142 Archive (ENA) under BioProject ID PRJEB41945. All accession numbers for the rest of the dataset are
143 available in Table S1.

144

145 **Acknowledgements:**

146 We thank Prof. Richard Goldstein (Division of Infection&Immunity, UCL) and Dr Daniel P. Depledge
147 (NYU Department of Medicine) for insightful comments and discussion. We acknowledge the
148 support of the MRC/NIHR funded Pathogen Genomics Unit.

149 CV was supported by the Wellcome Trust Collaborative Award [204870/Z/16/Z]; SM by a WT Henry
150 Wellcome fellowship [206478/Z/17/Z]. PJF was supported by MRC grant MR/S022597/1 and by NIHR
151 Imperial BRC. JB is supported by the NIHR UCL/UCLH BRC. This work was supported by the
152 intramural research program of the National of Allergy and Infectious Diseases.

153

154 Authorship contributions:

155 JB conceived the study, CV and JB designed the study and wrote the manuscript; CV performed
156 bioinformatics analysis with contributions from SoM and FW; AW, AR and PA were responsible for
157 care of the patients and provided clinical details. CH, AL, ZG collected clinical samples and data.
158 SDM JS, JIC, YT and PJF provided additional samples and data. All authors read and participate in
159 critical revision of the article.

160

161 Disclosure of conflicts of interest:

162 The authors declare no conflict of interest.

163

164 Reference:

- 165 1. Longnecker, R. M., Kieff, E. & Cohen, J. I. Epstein-barr virus. *Fields Virol. Sixth Ed.* (2013).
- 166 2. Cohen, J. I. *et al.* Characterization and treatment of chronic active Epstein-Barr virus disease: a
167 28-year experience in the United States. *Blood* **117**, 5835–5849 (2011).
- 168 3. Kimura, H. Pathogenesis of chronic active Epstein-Barr virus infection: Is this an infectious
169 disease, lymphoproliferative disorder, or immunodeficiency? *Rev. Med. Virol.* **16**, 251–261
170 (2006).
- 171 4. Ohshima, K., Suzumiya, J., Ohga, S., Ohgami, A. & Kikuchi, M. Integrated Epstein-Barr virus (EBV)
172 and chromosomal abnormality in chronic active EBV infection. *Int. J. Cancer* **71**, 943–947 (1997).
- 173 5. Kimura, H. & Cohen, J. I. Chronic Active Epstein–Barr Virus Disease. *Front. Immunol.* **8**, (2017).
- 174 6. Okuno, Y. *et al.* Defective Epstein–Barr virus in chronic active infection and haematological
175 malignancy. *Nat. Microbiol.* **4**, 404 (2019).
- 176 7. Peng, R.-J. *et al.* Genomic and transcriptomic landscapes of Epstein-Barr virus in extranodal
177 natural killer T-cell lymphoma. *Leukemia* **33**, 1451–1462 (2019).

- 178 8. Murata, T., Okuno, Y., Sato, Y., Watanabe, T. & Kimura, H. Oncogenesis of CAEBV revealed:
179 Intragenic deletions in the viral genome and leaky expression of lytic genes. *Rev. Med. Virol.* **30**,
180 e2095 (2020).
- 181 9. Cudini, J. *et al.* Human cytomegalovirus haplotype reconstruction reveals high diversity due to
182 superinfection and evidence of within-host recombination. *Proc. Natl. Acad. Sci.* **116**, 5693–5698
183 (2019).
- 184 10. Pang, J. *et al.* Haplotype assignment of longitudinal viral deep-sequencing data using co-
185 variation of variant frequencies. *bioRxiv* 444877 (2020) doi:10.1101/444877.
- 186 11. R Core Team. R: A language and environment for statistical computing. R Foundation for
187 Statistical Computing, Vienna, Austria. (2014).
- 188 12. Renzette, N. *et al.* EBV Latent Membrane Protein 1 genetic variability in peripheral blood B cells
189 and oropharyngeal fluids. *J. Virol.* JVI.03378-13 (2014) doi:10.1128/JVI.03378-13.
- 190 13. Kwok, H., Chan, K. W., Chan, K. H. & Chiang, A. K. S. Distribution, Persistence and Interchange of
191 Epstein-Barr Virus Strains among PBMC, Plasma and Saliva of Primary Infection Subjects. *PLOS*
192 *ONE* **10**, e0120710 (2015).
- 193 14. Lin, X. *et al.* The Epstein-Barr Virus BART miRNA Cluster of the M81 Strain Modulates Multiple
194 Functions in Primary B Cells. *PLoS Pathog.* **11**, (2015).
- 195 15. Ma, S.-D. *et al.* A New Model of Epstein-Barr Virus Infection Reveals an Important Role for Early
196 Lytic Viral Protein Expression in the Development of Lymphomas. *J. Virol.* **85**, 165–177 (2011).
- 197 16. Murata, T., Sato, Y. & Kimura, H. Modes of infection and oncogenesis by the Epstein–Barr virus.
198 *Rev. Med. Virol.* **24**, 242–253 (2014).
- 199 17. Ba abdullah, M. M. *et al.* Heterogeneity of the Epstein-Barr Virus (EBV) Major Internal Repeat
200 Reveals Evolutionary Mechanisms of EBV and a Functional Defect in the Prototype EBV Strain
201 B95-8. *J. Virol.* **91**, e00920-17, e00920-17 (2017).
- 202 18. Palser, A. L. *et al.* Genome Diversity of Epstein-Barr Virus from Multiple Tumor Types and
203 Normal Infection. *J. Virol.* **89**, 5222–5237 (2015).

204 Figure Legends

205 **Figure 1A: Viraemia and treatment in GOSH CAEBV patient.** Patient 1 and 3 received PBSCT (in red)
206 and all patients received 4 to 5 doses of rituximab (blue lines). Samples sequenced are indicated in
207 grey filled dots.

208 **Figure 1B: Summary of deletions (≥ 30 bp).** Samples for healthy (healthy-S), infectious
209 mononucleosis (IM-B), CAEBV (CAEBV-S, CAEBV-B), primary immunodeficiency (PID) as well as EBV-
210 positive solid organ transplant (SOT-B), PTLN (PTLN-B and PTLN-T) and HL (HL-T). Each line
211 represents an EBV genome from a single patient (if multiple samples from one patient were
212 available, only the one with the highest read depth was included here).

213 **Figure 1C: Representation of the IR1 deletion in CAEBV.** Representative portion of the alignment
214 file for a blood CAEBV sample to demonstrate IR1 deletion (represented by red reads and black
215 lines) compared to a IM blood sample where the deletion is not present (reads in grey).

216 **Figure 1D: Analysis of longitudinal samples in CAEBV patients.** Genes affected by larger deletions (\geq
217 2k) are shown in the heatmap; overtime all larger deletions are lost. Non-synonymous low frequency
218 variants (<50%) are shown in the bubble plot.


219

Pat	Sex	Description	Treatment	Transplant	Reactivation	N samples
P1	M	<ul style="list-style-type: none"> ○ EBV driven HLH ○ primary and secondary immunodeficiency excluded 	<ul style="list-style-type: none"> ○ HLH 94 protocol ○ 5 doses of Rituximab (pre-transplant) 	Alemtuzumab/Fludarabine/Melphalan conditioned matched unrelated donor (MUD) peripheral blood stem cell transplant (PBSCT)	4 months post HST had reactivation of EBV without signs of PTLD and resolved without therapy	7
P2	F	<ul style="list-style-type: none"> ○ EBV driven HLH ○ primary and secondary immunodeficiency excluded 	<ul style="list-style-type: none"> ○ HLH 94 protocol ○ 4 doses of Rituximab 	The patient did not proceed to BMT as she responded well to HLH treatment and had no evidence of ongoing HLH activity despite ongoing EBV viraemia	Remained EBV PCR positive for 3.5years without symptoms. As for November 2018 EBV PCR is negative.	3
P3	F	<ul style="list-style-type: none"> ○ EBV driven HLH, spontaneously resolved without treatment. ○ Over the following 6 months she had two further EBV-related HLH relapses treated with steroids. Although her HLH associated symptoms rapidly responded, her EBV viraemia continued to risk. ○ primary and secondary immunodeficiency excluded ○ During the 3rd HLH relapse treatment course patient had multiple complications (renal failure requiring haemofiltration, atrial fibrillation requiring DC cardioversion, adenovirus and CMV viremias, invasive candida parapsilosis enteritis, facial palsy) 	<ul style="list-style-type: none"> ○ 4 doses of rituximab with successfully depleted B cells but not reduced EBV viral load (pre-transplant) ○ After, 3rd HLH relapse and was commenced on etoposide as per HLH 94 protocol with resolution of clinical symptoms and reduction in EBV viral load. ○ 1 dose of rituximab after transplant 	Alemtuzumab/Fludarabine/Treosulfan conditioned matched sibling donor (MSD) peripheral blood stem cell transplant	EBV reactivation that resolved after 1 dose of Rituximab.	5


Table 1: Patients descriptions and clinical details. HLH= Haemophagocytic lymphohistiocytosis.

220
221
222


A)



B)



C)



D)

